CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: More importantly, S63845 did not enhance this well-known inhibitory effect of imatinib on normal CD34+ hematopoietic stem/progenitor cells, suggesting a potential therapeutic window to efficiently target CML stem/progenitor cells without affecting the normal hematopoietic stem/progenitor cell population.